The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.
1) Client Situation
The client operated within the therapeutics-focused biotech ecosystem and required support with Companion Diagnostic And Combination Product Regulatory Strategy in the context of Biotechnology. Organizations across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators requested an integrated regulatory strategy for companion diagnostics (CDx) and drug–device combination products. Leaders sought to classify products correctly, plan co-development and submission pathways, and coordinate interactions with FDA centers (CDER/CBER and CDRH/OHTs) and EMA/Notified Bodies to synchronize approvals and enable precision therapy access. The diagnostic we conducted surfaced critical risks and gaps:
- Ambiguous product classification and regulatory ownership
- Primary mode of action (PMOA) was not explicitly documented for drug–device combinations; constituent-part boundaries were unclear (e.g., on-body injector vs. prefilled syringe vs. autoinjector). No Request for Designation (RFD) or informal engagement with the FDA Office of Combination Products (OCP) had been planned to clarify lead center and review combination arrangements.
- Diagnostic intent oscillated between “companion” and “complementary” labeling; teams had not converged on the regulatory implications for PMA vs. 510(k)/De Novo pathways, nor on the clinical evidence to support treatment selection language in USPI/SmPC.
- Disjointed CDx–therapeutic co-development
- Analytical and clinical validation (AV/CV) plans for the IVD were not aligned to pivotal trial timelines; bridging strategies for assay changes (platform migration, cut-point updates, reagent lots) were not codified; archived specimen sufficiency was uncertain.
- Laboratory-developed test (LDT) use in early trials lacked a clear path to transition to an FDA-cleared/approved IVD for registrational studies; CLIA complexity, site readiness, and proficiency testing were not harmonized across geographies.
- Global regulatory divergence underestimated
- EU IVDR classification (Class C for most predictive CDx) and Notified Body (NB) consultation with the relevant medicines authority were not integrated into planning; timelines for NB capacity and performance evaluation were optimistic. UKCA and other reliance pathways were not addressed.
- MDR drug–device combination Article 117 expectations for device evidence within an MA dossier were underappreciated; PSUR/PMCF/PMCF-equivalent and PSUR/PSMF linkages were undefined.
- Insufficient device design control and usability planning
- 21 CFR 820.30 design control deliverables (user needs, design inputs/outputs, risk management files per ISO 14971, verification/validation, formative/summative human factors) were not scheduled; IFU and training impacts on risk controls were not mapped.
- Software-in-the-loop (SaMD/SiMD) elements (NGS bioinformatics pipelines, instrument firmware, mobile apps for on-body delivery) lacked cybersecurity and software lifecycle planning (IEC 62304/81001-5-1), and premarket documentation outlines.
- Clinical strategy not aligned to labeling ambition
- Biomarker hypothesis, cutpoint determination, and assay-to-biology link were not presented in a regulator-ready narrative; plans for prospective–retrospective analyses vs. pre-specified biomarker-enriched designs were not assessed against review precedent.
- Specimen handling SOPs (preanalytical variables), concordance plans (positive/negative percent agreement vs. clinical outcome), and inter-site reproducibility for the trial assay were not fully defined.
- Submission and meeting choreography unclear
- Q-Submissions (Pre-Sub) to CDRH and Type B/C interactions with CDER/CBER were not sequenced; briefing packages lacked crisp “asks” and integrated cross-center positions; meeting minute negotiation strategies were not documented.
- eSTAR/eCopy device submissions, eCTD cross-referencing for drug files, and cross-licensing of data between centers and partners were not rehearsed; redaction and confidentiality positions were not harmonized with partners.
- Supplier and partner oversight risk
- IVD manufacturer QMS maturity (ISO 13485), lot release and change control, and design transfer readiness were not fully assessed; cross-organization RACIs for complaint handling, vigilance (MDR/IVDR), and field safety corrective actions were undefined.
- Commercialization and access misalignment
- Payer evidence (MolDx Technical Assessment, LCD/NCD prospects) and HTA expectations for CDx clinical utility were not integrated; distribution and training for device constituents (on-body injector IFU, needle-stick prevention) were handled as late-stage activities.
Signals included: late protocol amendments to incorporate biomarker stratification; assay-platform changes mid-development without bridging plans; uncertainty over PMA vs. De Novo for NGS-based tests; varied interpretations of EU IVDR NB timelines; and unplanned negotiations with FDA centers on review coordination. Executive sponsors requested a robust, regulator-facing CDx and combination product strategy that synchronized evidence, submissions, and inter-agency engagement.
2) Project Objective
The primary objective focused on defining and operationalizing a global regulatory strategy for companion diagnostics and drug–device combination products—covering classification, co-development, validation, and submission pathways—while coordinating FDA/EMA/Notified Body interactions to synchronize approvals and enable precision therapy access.
Secondary objectives included:
- Establishing classification and lead-center alignment (PMOA analysis, OCP RFD as needed) and defining constituent-part boundaries and responsibilities.
- Designing an integrated CDx–drug development plan (analytical/clinical validation, bridging, specimen strategy) aligned to pivotal trials and labeling ambitions.
- Selecting and documenting US pathways (PMA/510(k)/De Novo; IDE/NSR determinations; Q-Subs) and EU/UK/JP IVDR/MDR/MHLW requirements and timelines.
- Embedding device design control, usability/human factors engineering, risk management (ISO 14971), software lifecycle, and cybersecurity into the program plan.
- Sequencing meetings and submissions across centers and regions (CDER/CBER with CDRH; EMA/CHMP with NB consultation) and orchestrating consistent positions and minutes.
- Setting up regulatory operations (eSTAR/eCopy and eCTD cross-referencing), data sharing across partners, and vendor governance (ISO 13485 QMS, change control).
- Integrating payer/HTA CDx expectations into evidence and labeling strategy to support coverage and access.
3) Methodology and Approach
Workstream 1: Classification, PMOA, and Combination Product Pathway
We clarified regulatory jurisdiction, constituent parts, and lead review centers.
- PMOA analysis: documented therapeutic mechanism of action and device role to determine PMOA per 21 CFR Part 3; assessed whether the combination constituted a single-entity, co-packaged, or cross-labeled product.
- OCP engagement: prepared and, where warranted, submitted an RFD to the Office of Combination Products; ran pre-RFD interactions to align expectations; captured OCP designation and assignment of primary and consulting centers (e.g., CDER primary with CDRH consult).
- Constituent boundaries: delineated design control and cGMP/QSR responsibilities (21 CFR 210/211 and 820); created RACIs for complaint handling, vigilance, field actions, post-market safety and performance (PMS/PSUR/PMCF) where applicable.
Workstream 2: Companion vs. Complementary Diagnostic Positioning
We aligned labeling ambition with evidence strategy and regulatory pathway.
- Diagnostic intent: defined whether the biomarker was essential for safe and effective use (companion) or supportive (complementary); mapped label language implications (USPI Indications & Usage, Dosage & Administration, Warnings/Precautions).
- Pathway selection: selected PMA (typical for CDx) vs. 510(k)/De Novo based on predicate landscape and novelty; for NGS-based tests, assessed special controls and bioinformatics diligence.
- Clinical utility and coverage: integrated payer expectations (e.g., MolDx) into CV/clinical utility planning to support reimbursement upon approval.
Workstream 3: Analytical and Clinical Validation (AV/CV) and Bridging
We designed validation approaches to withstand regulatory scrutiny and operational realities.
- Analytical validation: defined performance characteristics (LOD/LOQ, precision/repeatability/reproducibility, analytical sensitivity/specificity, reportable range, inclusivity/exclusivity, interference, stability) and acceptance criteria; addressed preanalytical variables (specimen type, fixation, transport).
- Clinical validation: designed concordance studies (positive/negative percent agreement) relative to clinical outcome; tailored CV to biomarker class (IHC, FISH/ISH, PCR, NGS-based variant calling, gene expression signatures); managed cutpoint determination and lock procedures.
- Bridging: authored bridging plans for platform changes (assay migration), reagent/lot changes, and post-approval updates; ensured sufficient archived specimens and statistical power for revalidation; documented change control within ISO 13485 QMS.
Workstream 4: Clinical Trial Integration and Trial Assay Strategy
We aligned trial design, assay deployment, and specimen logistics to support labeling.
- Trial assay vs. to-be-marketed assay: defined whether the clinical trial assay (CTA) was identical to the IVD or required bridging; documented equivalence strategies and acceptance criteria.
- IDE/NSR determinations: assessed whether the diagnostic studies required IDE; sought FDA feedback via Q-Sub; ensured CLIA site readiness and training for CTA operation; standardized specimen handling SOPs.
- Biomarker strategy: framed enrichment vs. all-comers with prospective–retrospective analysis; locked cutpoints and analysis plans consistent with estimands; embedded re-testing plans if assay updates occurred.
Workstream 5: Design Controls, Human Factors, and Risk Management
We embedded device rigor across diagnostic and delivery-device constituents.
- Design control: established DHF artifacts (user needs, inputs, outputs, verification/validation, design reviews, trace matrices); coordinated with partners on design transfer to manufacturing.
- Human factors engineering: executed formative and summative HF studies for autoinjectors/on-body devices/IFU per FDA guidance; integrated risk controls into labeling and training.
- Software lifecycle and cybersecurity: documented IEC 62304 classification for SaMD/SiMD; prepared SBOM, cybersecurity risk management (FDA premarket guidance), and verification for bioinformatics pipelines.
Workstream 6: FDA/EMA/NB Engagement and Meeting Strategy
We orchestrated cross-center interactions and preserved strategic optionality.
- Q-Subs and Type B/C meetings: sequenced CDRH Pre-Sub and CDER/CBER interactions; authored integrated briefing packages with crisp “asks,” data summaries, and fallback propositions; rehearsed cross-functional teams; managed minute negotiations.
- EU IVDR/MDR pathway: aligned with a Notified Body on performance evaluation and conformity assessment (likely Class C for CDx); coordinated NB consultation with a competent authority for drug–device interfaces (Article 117) where relevant; planned technical documentation and PSUR/PMS obligations.
- Global convergence: mapped Health Canada, PMDA, and UKCA expectations; assessed reliance opportunities and dossier tailoring; captured regional divergences and harmonization plan.
Workstream 7: Submissions Architecture and Publishing
We ensured the operational capability to file synchronized, technically conformant submissions.
- Device submissions: prepared eSTAR (for PMA or 510(k)/De Novo as applicable) or eCopy packages for CDRH; structured performance data modules and IFU; validated DICOM/NGS file formats where required; prepared IDE documents if needed.
- Drug submissions: created eCTD cross-references to device dossiers; aligned Module 3/5 content to diagnostic claims; ensured consistent labeling language and data linkage.
- Data rights: executed cross-licenses and DMFs/MAFs or right-of-reference letters between partners; documented secure data-sharing and confidentiality safeguards.
Workstream 8: Post-Approval Planning and Change Management
We set the foundation for lifecycle agility without jeopardizing labeling or access.
- Postmarket obligations: defined PMA conditions (real-world performance, complaint trend reporting, CAPA); prepared IVDR PMS/PSUR plans and vigilance SOPs; synchronized with drug RMPS/REMS where needed.
- Updates and bridging: pre-planned minor updates (software versioning, assay lot changes) with bridging criteria; evaluated PACMP-like constructs for diagnostics where acceptable; codified change control and revalidation steps.
- Supply and training: aligned distribution plans for the diagnostic and combination device; developed training materials synchronized with IFU; prepared field support and adverse event reporting flows.
Workstream 9: Payer/HTA Strategy Integration
We linked regulatory choices to access and adoption.
- Coverage criteria: aligned clinical utility arguments with MolDx/HTA expectations; prepared analytic validity and clinical validity summaries in payer-friendly formats.
- Economic models: integrated time-to-result, testing pathways, and responder-enrichment into early economic models; ensured consistency with label and IFU claims.
Workstream 10: Governance, Vendor Oversight, and Program Controls
We established decision discipline and partner accountability.
- Governance: stood up an integrated regulatory steering committee (drug, device, diagnostics) with decision gates (assay lock, AV/CV completion, Q-Sub submissions, pivotal start, submission readiness); aligned with portfolio and quality councils.
- Vendor oversight: assessed IVD partner QMS (ISO 13485), supplier control, lot release, and design transfer; implemented QBRs with KPIs (on-time deliverables, validation readiness, response to audit findings).
- Controls: instituted risk register, RACI, and documentation standards (traceability from clinical outcomes to diagnostic claims; PMOA rationale; meeting minutes and commitments).
4) Data Request
We requested datasets and artifacts required to build and execute the CDx and combination product regulatory strategy. Typical horizons included current development documents and 12–36 months of forward plans.
- Product and biology
- Therapeutic MOA, biomarker rationale, target population estimates, preclinical and clinical evidence summaries, cutpoint hypotheses, enrichment plans.
- Assay and validation
- Assay technical files, AV protocols/reports (LOD/LOQ, precision, specificity), preanalytical SOPs, inter-site reproducibility data, bioinformatics pipeline documentation (if NGS), HF/IFU drafts, cybersecurity artifacts.
- Clinical trials
- Protocols and SAPs with biomarker elements, CTA vs. IVD equivalence strategy, IDE/NSR determinations, specimen inventory and consent language, site readiness/CLIA status.
- Regulatory history and precedents
- Prior FDA/EMA/NB interactions, advice minutes, precedent labels and review summaries, class labeling guidance, PMOA analyses and any RFD materials.
- Quality and design
- QMS certificates (ISO 13485), DHF/DMR/DHR summaries, risk management files (ISO 14971), design verification/validation plans, supplier controls, change control procedures.
- Submissions and operations
- Publishing toolchain details (eSTAR/eCopy/eCTD), data-sharing agreements, sample submission sequences, redaction plans, portal access credentials, technical validation checklists.
- Commercial and access
- Coverage/HTA insights, diagnostic distribution model, training plans, field support SOPs, pricing and contracting strategy (where available).
- Program controls
- Integrated timelines (drug and device), budget/resource plans, vendor contracts and SLAs, risk registers.
Common data pitfalls included incomplete analytical validation for novel assay components, insufficient archived specimens for bridging, unclear trial assay–IVD equivalence, missing PMOA classification documentation, absence of HF evidence for delivery devices, fragmented QMS assurance for IVD partners, and untested eSTAR/eCTD publishing processes. We established a controlled data room and a traceability framework before formal agency engagements.
5) Questions for Client
- What diagnostic intent (companion vs. complementary) best aligns with your TPP, and what claims must the label carry in US/EU?
- Which PMOA and constituent-part boundaries are assumed; do you want to seek an OCP RFD to lock lead center and consults?
- What is the to-be-marketed assay relative to the CTA; what bridging (platform migration, cutpoint, reagent) do we need to plan?
- Which analytical and clinical validation endpoints are non-negotiable; how will we handle preanalytical variability across sites?
- What US pathway (PMA vs. 510(k)/De Novo) and EU IVDR classification do you target; what Notified Body capacity and timeline constraints exist?
- What meeting sequence (Q-Subs, Type B/C) should we plan; what integrated “asks” require cross-center alignment?
- Which design control, HF, and software lifecycle artifacts exist today; where are the largest gaps?
- Which vendors (IVD manufacturer, device components) will carry which QMS responsibilities; what assurance is available?
- What is your coverage strategy for the diagnostic (e.g., MolDx), and what clinical utility evidence will support it?
- What risk tolerance exists for prospective enrichment vs. retrospective analyses; how will we manage sample availability and consent?
- What synchronization milestones are fixed (pivotal FPI/DBL, submission dates), and what buffers are acceptable?
6) Interview Guide for Subject Matter Experts
Global Regulatory Lead (Drug)
- What FDA/EMA precedents are most relevant for labeling and expedited pathways; where do you anticipate pushback?
- How do you envision cross-center meeting choreography; what are the critical “asks”?
- What are your non-negotiable synchronization dates for drug and diagnostic submissions?
IVD Regulatory/Quality Lead (Partner or Internal)
- Which AV/CV studies are complete or planned; where are specimen and bridging constraints most acute?
- What QMS readiness exists (ISO 13485, change control, supplier oversight); how will design transfer be evidenced?
- What EU IVDR classification and NB path do you expect; what is the performance evaluation strategy?
Clinical Development / Biomarker Lead
- How do biomarker hypotheses map to protocol endpoints; what is the cutpoint strategy and lock timing?
- Will the CTA match the IVD at pivotal start; if not, what is the bridging plan?
- What are the operational risks (site training, specimen handling, turnaround times) and mitigations?
Biostatistics / Data Science (NGS/Bioinformatics)
- What statistical approaches support concordance and clinical validation; how robust are sensitivity analyses?
- How is the bioinformatics pipeline validated; what versioning and cybersecurity controls apply?
- What is the analytical and clinical impact of cutpoint or algorithmic changes?
Device Engineering / Human Factors
- What user needs and hazards drive IFU content; what formative/summative HF is planned; where are usability risks highest?
- How are risk controls traced to design outputs and labeling; what residual risks require training?
Regulatory Operations / Publishing
- What eSTAR/eCopy/eCTD tooling and SOPs exist; where have technical validation errors recurred?
- How will we manage cross-references and data-sharing between partners; what redaction plans are feasible?
Market Access / Reimbursement
- What payer criteria will govern CDx coverage; what clinical utility evidence and testing pathway assumptions must we support?
- How should labeling and IFU language anticipate payer reviews?
Office of Combination Products Liaison / Legal
- What PMOA evidence and RFD strategy are preferred; how will we structure data-sharing and cross-references?
- What IP or confidentiality constraints shape submission timing and content?
7) Timeline
We executed a 12–14 week plan tailored to Companion Diagnostic & Combination Product Regulatory Strategy within Regulatory Affairs.
- Weeks 1–2: Diagnostic and Strategy Framing
- Assessed current biomarker, assay, and clinical plans; reviewed precedent; mapped PMOA and constituent parts; drafted initial classification and pathway options; created integrated milestone map (drug and device).
- Decision Gate A: Approved diagnostic intent (companion vs. complementary), PMOA assumptions or RFD decision, and preliminary US/EU pathway selections.
- Weeks 3–4: AV/CV and Clinical Integration
- Finalized AV/CV strategies, bridging plans, and specimen logistics; aligned CTA–IVD equivalence approach; embedded IDE/NSR determinations and site readiness; refined trial endpoints and cutpoint lock plans.
- Decision Gate B: Endorsed validation and bridging plans, CTA deployment approach, and trial design implications.
- Weeks 5–6: Design Control, HF, and Software Lifecycle
- Built DHF framework and risk management files (ISO 14971); scheduled formative/summative HF; defined cybersecurity/SBOM and software lifecycle controls for SaMD/SiMD; aligned training and IFU updates to risk controls.
- Decision Gate C: Confirmed design control artifacts and HF plans; locked software lifecycle documentation outline.
- Weeks 7–8: FDA/EMA/IVDR Engagement Preparation
- Drafted integrated Q-Sub and Type B/C briefing packages with explicit “asks”; prepared EU IVDR NB engagement materials; rehearsed teams and negotiation positions; confirmed Notified Body capacity and timelines.
- Decision Gate D: Cleared meeting packages and roles; set minute negotiation strategies; validated NB pathway assumptions.
- Weeks 9–10: Submissions Architecture and Operations
- Configured eSTAR/eCopy and eCTD cross-references; established data-sharing and redaction protocols; ran technical validation dry-runs; confirmed portal access and backup channels.
- Decision Gate E: Approved submissions architecture and publishing SOPs; authorized meeting requests and dossier content build.
- Weeks 11–12: Post-Approval and Access Alignment
- Outlined post-market obligations (PMA conditions, PMS/PSUR), change control and bridging criteria; integrated payer/HTA requirements with clinical utility evidence; aligned distribution and training plans.
- Decision Gate F: Endorsed lifecycle and access plans; scheduled follow-on engagements and quarterly strategy refresh cadence.
- Weeks 13–14 (optional): Cross-Center Mock and Risk Drill
- Conducted simulated joint FDA center meeting; executed end-to-end publishing drill; tuned risk register and mitigations; finalized cross-partner governance and QBR cadence.
Critical path items included PMOA and lead-center clarity, AV/CV completeness and specimen availability, CTA–IVD equivalence or bridging, EU IVDR NB capacity and scheduling, HF and software lifecycle documentation, and submissions architecture readiness across eSTAR/eCTD with partner data-sharing.
8) Deliverables
- Integrated CDx & Combination Product Strategy Dossier
- Classification and PMOA rationale, diagnostic intent (companion/complementary), US/EU/JP pathways, synchronized milestones, and risk register with mitigations.
- AV/CV and Bridging Plan
- Analytical validation protocols/acceptance criteria, clinical validation/concordance designs, CTA–IVD equivalence strategy, specimen management, and change-bridging criteria.
- Design Control & Risk Management Pack
- DHF index and templates, ISO 14971 risk file, HF plans and protocols, software lifecycle and cybersecurity documentation outlines; training/IFU linkage.
- FDA/EMA/IVDR Engagement Toolkit
- Q-Sub and Type B/C briefing books with “asks,” data summaries, and fallback positions; NB engagement package; stakeholder role scripts and minute negotiation playbook.
- Submissions Architecture & Publishing SOPs
- eSTAR/eCopy structures, eCTD cross-reference plan, redaction policy, portal access verification, technical validation checklists, and drill reports.
- Vendor & Partner Governance Framework
- QMS assessment summaries, RACIs, QBR scorecards (on-time readiness, validation pass rates), escalation ladders, and change-control alignment.
- Labeling & Access Alignment Brief
- USPI/SmPC diagnostics language strategy, clinical utility evidence plan, payer/HTA alignment, and training/distribution considerations for launch.
- Post-Market Surveillance & Change Plan
- PMA conditions, PMS/PSUR plans, vigilance SOPs, and lifecycle bridging criteria for updates (software versions, lot changes); alignment with drug REMS/RMP.
- Inspection Readiness & Evidence Binders
- Traceability from outcomes to diagnostic claims, AV/CV reports, DHF/HF/Cybersecurity artifacts, meeting minutes and commitments, and publishing evidence.
- Executive & Board Pack
- Timeline, regulatory path, coordination plan across centers and regions, key risks and mitigations, vendor readiness, and resource/budget implications.
9) Industry Insights
- CDx is often a PMA in the US and Class C under IVDR
- Most predictive CDx require PMA-level evidence in the US and face IVDR Class C conformity assessment with NB consultation in the EU; timelines and resource needs must be planned accordingly.
- Companion vs. complementary has labeling and evidence stakes
- “Companion” language demands robust AV/CV with outcomes linkage; “complementary” can be supported with less stringent evidence but may limit claims and payer coverage.
- Bridging is inevitable—design it early
- Platform migrations, reagent changes, and software updates occur; pre-specifying bridging criteria and specimen plans reduces late-stage risk and decouples updates from clinical milestones.
- Design control and HF determine reliability and label
- Human factors and risk controls underpin IFU and training; gaps drive corrective cycles and can slow approvals. SaMD/SiMD cybersecurity expectations now influence premarket reviews.
- Joint FDA center choreography improves outcomes
- Coherent cross-center “asks,” clear roles, and minute strategies reduce conflicting feedback and review churn; Q-Subs remain an effective forum when prepared crisply.
- IVDR capacity is a gating constraint
- Notified Body availability and performance evaluation requirements elongate schedules; early NB engagement and complete technical documentation avoid bottlenecks.
- Payer coverage hinges on clinical utility, not only validity
- MolDx and HTA decisions require evidence that testing changes management and outcomes; integrating utility endpoints early strengthens adoption.
- What “good” looks like
- A clear PMOA and lead-center designation; aligned CDx–drug intent and claims; robust AV/CV and bridging plans; integrated clinical and assay strategies; documented design control/HF/cybersecurity; synchronized FDA/EMA/NB engagements; ready submissions architecture; and a post-market plan aligned to access and lifecycle agility.
- Near-term watch points
- Evolving FDA policy on LDT oversight and implications for trial assays; IVDR implementation pressure and NB capacity; cybersecurity expectations for SaMD; payer scrutiny of CDx utility; and cross-center coordination for combination products. Quarterly strategy refreshes maintain alignment with shifting guidance.
Implications for clients we served included enabling Emerging Therapeutic Biotech to lock classification and co-development plans before first-in-human; supporting Clinical-Stage Biotech to align pivotal designs and assay strategies with CDx PMA timing; equipping Commercial Biotech to synchronize combination device and diagnostic approvals for launch; guiding Platform Biotech to standardize CDx/combination product playbooks across partnered programs; and providing Biotech Investors & Incubators with transparent regulatory path, synchronization risk, and vendor readiness views across portfolios.
